BUZZ-Monte Rosa 因准备开展晚期前列腺癌新组合试验而上涨

路透中文
Mar 16
BUZZ-Monte Rosa 因准备开展晚期前列腺癌新组合试验而上涨

3月16日 - ** 生物技术公司Monte Rosa Therapeutics GLUE.O股价盘前上涨5.1%至16.85美元

** 该公司称将开始对其实验性前列腺癌药物MRT-2359与强生公司JNJ.N的Erleada进行中期研究

** 试验将在对激素疗法不再有反应的晚期前列腺癌患者中测试这种组合疗法,这是一种难以治疗的疾病 - GLUE

** MRT-2359是一种口服实验药物,旨在分解一种帮助癌细胞存活的蛋白质,该公司表示。

** 该研究预计将于 2026 年第三季度开始,最多将招募 25 名患者,由 Monte Rosa 负责试验,J&J 提供 Erleada - GLUE

** 公司表示,Erleada已被批准用于治疗某些前列腺癌;研究将跟踪PSA水平、肿瘤大小和疾病进展情况

** 2025 年股价上涨约两倍

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10